Printer Friendly

Effects of Cardiac Hypertrophy, Diabetes, Aging, and Pregnancy on the Cardioprotective Effects of Postconditioning in Male and Female Rats.

1. Background

Ischemic heart disease (IHD) remains a global health concern, and acute myocardial infarction continues to be a leading cause of death [1]. Restriction of coronary blood supply leads to myocardial infarction which is the primary determinant of disease prognosis [1]. The infarct size and disease outcome can remarkably be improved by restoration of blood flow by reperfusion [2]. However, reperfusion itself can be devastating resulting in significant damage within the ischemia-affected area [2]. Several cardioprotective strategies have been developed to limit the destructive effects of ischemia/reperfusion (I/R) injury on the myocardium. These include, but are not limited to, the application of brief sublethal ischemic episodes at the beginning of reperfusion on-site or a distant vascular bed (ischemic postconditioning and remote ischemic postconditioning, respectively) [3, 4]. More recently, a modification of the remote postconditioning maneuver has been introduced which involves changing myocardial stretch pattern via remote electrical stimulation of the heart chambers (pacing postconditioning (PPC)) [5]. We have reported that PPC is an effective protective postconditioning maneuver against I/R injury in experimental animals [5-7]. We have further investigated the molecular mechanisms involved in PPC-induced cardiac protection [8-10]. The first clinical application of the PPC maneuver demonstrated significant decrease in infarct size in ST-segment elevation myocardial infarction (STEMI) patients [11]. This, however, was accompanied by arterial and ventricular fibrillation [11]. Additional clinical studies would, therefore, require further technical optimization and more comprehensive consideration of various clinical scenarios existing in MI patients that could potentially attenuate the cardioprotective properties of PPC or may cause undesirable side effects.

Aging-induced structural and functional changes in the cardiovascular system were linked to increased incidence of CVD in the elderly [12]. Aging is a common risk factor in MI patients and reduces patients' tolerance to ischemia and imposes a significant impact on disease prognosis [13, 14]. Ischemic postconditioning-induced cardiac protection was attenuated in senescent mice [15]. The efficiency of PPC-induced cardiac protection in aging remains to be established.

Increased susceptibility of hypertrophied heart to ischemia [16] and postischemic arrhythmias [17] were previously reported. Available evidence on the efficiency of ischemic postconditioning strategies in attenuating ischemic injury in the presence of LVH is contradictory, possibly due to use of different LVH models [18, 19]. LVH has been associated with increased mortality from MI [20]. Thus, the identification of effective maneuvers for the protection of hypertrophied hearts is essential.

Patients with type 1 and type 2 diabetes are prone to cardiovascular diseases [21], and IHD remains to be a significant source of morbidity and mortality in these patients. Increased risk of ischemic events and poor recovery after an acute MI event were demonstrated in diabetic patients [22]. Inconsistent data from experimental models were reported on the susceptibility of diabetic heart to ischemic injury [23, 24]. The available data on the efficacy of postconditioning strategies in protecting the diabetic heart from ischemic injury are equivocal [25,26], possibly due to the use of different experimental models and conditioning protocols. We have previously reported that seven cycles of alternating left and right ventricular pacing for 30 seconds each to a minimum of 200 seconds did not protect diabetic rabbit hearts from I/R injury [25]. Nonetheless, the effect of PPC in protecting diabetic rodent hearts against ischemic injury has not been previously given consideration.

There is a notable increase in the incidence of IHD in pregnancy in the recent years, possibly due to the increasing maternal age, higher prevalence of cardiac risk factors, and change of some social habits like smoking [27]. Enhanced risk of IHD and deteriorated prognosis were reported in pregnancy [27]. Pregnancy causes significant changes in cardiac hemodynamics which could ultimately lead to IHD [28]. Also, increased cardiac workload and increased myocardial oxygen demand during pregnancy may cause severe IHD [29]. Although many treatment regimens were used in treating IHD during pregnancy, postconditioning data in animal models or clinical studies are lacking [6, 30].

In this study, we were set to investigate the efficacy of PPC maneuver in protection against I/R injury in male and female rats in the presence of clinically relevant scenarios including aging, LVH, diabetes mellitus, and pregnancy.

2. Materials and Methods

2.1. Materials. All materials were purchased from Sigma-Aldrich (St. Louis, Missouri) unless stated otherwise.

2.2. Animals and Procedures. Animal treatments and handling were performed according to the laboratory animal care guidelines of Kuwait University in accordance with International Guide for the Care and Use of Laboratory Animals (Eighth edition, 2011). In this study, we followed methods and procedures used in our previous studies [6, 25, 31]. Age-matched male and female Sprague-Dawley rats weighing between 210 and 370 g were used in this study. The rats were maintained at 22[degrees]C on a 12-hr light/dark cycle (7 am-7 pm), and water and food were provided ad libitum. A total of 128 rats were subdivided into 16 groups (n = 8 per group) and were subjected to 4 different experimental protocols, as summarized in (Figure 1). All rats used in the study are 20 weeks old unless otherwise stated. To study the effects of aging and LVH, hearts from 20-month-old male and female SD rats and spontaneously hypertensive rats (SHR) were used, respectively. For experiments on diabetic hearts, diabetes was induced by a single intraperitoneal injection of 55mg/kg body weight streptozotocin (STZ) as described previously [32]. Basal glucose levels were determined before the STZ injection and 48 hr after injection. Blood glucose concentration of 250 mg/dL was used as a cutoff value. Rats with blood glucose concentrations more than 250 mg/dL were declared diabetic while rats that did not meet this criterion were excluded from the study [33]. The animals' diabetic state was re-assessed six weeks later, just before sacrifice. For pregnancy studies, rats were mated overnight. The next day, vaginal smears were examined for the presence of sperms. Females with sperm-positive smear were identified as pregnant and designated day 0 of pregnancy as described previously [34]. These rats were weighed and individually housed in Plexiglas cages undisturbed until day 19 or 21 of gestation when they were sacrificed. 19 and 21 gestation days were selected based on the critical changes in the pregnancy progress in these animals [35].

Anesthesia was administered via an intraperitoneal injection of sodium pentobarbital (60 mg/kg). Heart cannulation and perfusion were performed as described previously [6]. Briefly, the isolated heart was retrogradely perfused with freshly prepared Krebs-Henseleit buffer. Oxygenation was performed using a mixture of C[O.sub.2] (5%) and [O.sub.2] (95%) at a temperature of 37.0 [+ or -] 0.5[degrees]C. Heart instrumentation included placing pacing electrodes on the right atrium (RA) appendage to maintain physiological heartbeats. Regional ischemia was induced by occluding the left coronary artery for 30 min. Under the basal control conditions, the preload was held constant at 6 mmHg. The perfusion pressure (PP) was held constant at 50 mmHg throughout the experimental procedure in all protocols. The PP was measured immediately downstream of the flow probe from a branch of the aortic cannula using a Statham pressure transducer (P23 Db). Constant PP was ensured electronically using the perfusion assembly (Module PPCM type 671, Hugo Sachs Elektronik, Harvard Apparatus GmbH, Germany), an effective system for accurate adjustment of PP between 5 mm Hg and 150 mm Hg with an accuracy of [+ or -] 1 mmHg.

2.3. Study Protocol. All hearts were subjected to 30 min of ischemia produced by left coronary artery occlusion as described previously by Khalaf et al. [31]. Briefly, the left coronary artery was encircled by a snare approximately 0.5 cm below the atrioventricular (AV) groove, and a small rigid plastic tube was positioned between the heart and the snare to ensure complete occlusion of the coronary artery. Afterward, the hearts were reperfused for 30 min. Control hearts were subjected to I/R injury without any further treatment. The PPC involved three alternate RA and LV pacing episodes for 30 sec each. The on-and-off pacing cycles were selected based on our previous studies [10, 25]. The pacing electrode was fixed to the posterior basal LV wall and connected to a pacemaker set to the required pacing frequency. Simultaneous AV pacing (AV interval = 0 ms) was used for LV pacing to ensure complete ventricular activation in response to stimulation from the pacing electrode.

2.4. Evaluation of Heart Function. Left ventricular hemodynamics, contractility, and coronary-vascular dynamics were evaluated during stabilization, ischemia, and reperfusion periods. The LV dynamics were determined throughout the experiment by assessing the LV enddiastolic pressure (LVEDP), the maximum developed pressure (DPmax), and LV contractility (+dP/dt or -dP/ dt). The coronary vascular dynamics were evaluated by assessing coronary flow (CF) and coronary vascular resistance (CVR). Cardiovascular functions were measured as previously described [6, 25, 31]. Briefly, a water-filled latex balloon was placed and secured in the LV cavity. The balloon was attached to a pressure transducer and a direct current bridge amplifier (DC-BA) equipped with a pressure module (DC-BA type 660, Hugo-Sachs Electronik, Germany) and interfaced to a personal computer for online monitoring of DPmax. The LVDP data were derived from online acquisition of LVEDP using the Max-Min module (Number MMM type 668, Hugo Sachs Elektronik, Harvard Apparatus GmbH, Germany), which converts the output from the DC-BA to DPmax by subtracting LVEDP.

CF was continuously measured using an electromagnetic flow probe attached to the inflow of the aortic cannula interfaced to a personal computer as described previously in Khalaf et al. [31]. The continuous monitoring of CF in ml/ min was digitally monitored using the software developed by Hugo-Sachs (Hugo-Sachs Electronik, Germany) specifically for this purpose and was manually verified via the timed collection of the coronary effluent. The CVR and hemodynamic data were recorded every 10 sec using an online data acquisition program (Isoheart software V 1.524-S, Hugo-Sachs Electronik, Germany). At the end of each experiment, the heart was snap-frozen in liquid nitrogen and stored at -80[degrees]C for further analysis.

2.5. Evaluation of Cardiac Injury by Measurements of Infarct Size and Cardiac Enzymes Levels. The infarct size was determined by triphenyltetrazolium chloride (TTC) staining. Hearts were collected after 30 min of reperfusion and stored overnight at -20[degrees]C. The next day, each heart was sliced into 4-5 pieces from its apex to base along the long axis. The slices were then incubated for 15 min in 1% TTC solution in isotonic phosphate buffer (pH 7.4) at 37[degrees]C and fixed in 4% formaldehyde. Images were taken using Nikon camera. Red and pale unstained areas of every slice were indicated manually on the image using Leica ImageJ (Image J, Wayne Rasb and National Institute of Health, USA). The percentage infarct area was calculated relative to total LV area. Cardiomyocyte injury was evaluated by measuring creatine kinase (CK) and lactate dehydrogenase (LDH) release in the coronary effluent during the reperfusion period as previously described [36].

2.6. Data Analysis. Data were analyzed by two-way analysis of variance (ANOVA) followed by the least significant difference (LSD) post hoc analysis using SPSS software. Comparisons were performed between group means and the mean for their respective controls. The data were presented as the mean [+ or -] standard error of the mean and differences were considered statistically significant at P < 0.05.

3. Results

3.1. PPC Maneuver Provided Cardiac Protection in Aged Female but Not in Male Rats. To address the role of age and gender, the effectiveness of PPC in protecting against I/R injury was evaluated in young (four months) and old (twenty months) male and female rats. There were no significant differences in the heart or body weights corrected to tibia length (mg/mm and g/mm, respectively) between young or old males and females. Heart functions were evaluated by the recovery of LV dynamics (DPmax and LVEDP), LV contractility (+dP/dt or -dP/dt), and coronary vascular dynamics (CF and CVR). Baseline changes in the LV dynamics and coronary vascular dynamics during baseline RA pacing were similar in young and aged male and female rats. Index Ischemia resulted in a significant (P < 0.001) deterioration in LV dynamics and coronary vascular dynamics compared to baseline (Figure 2). The vulnerability of hearts isolated from aged male and female rats to I/R injury was not significantly different from hearts isolated from younger male and female rats (Figure 2). The PPC intervention significantly (P < 0.05) improved LV dysfunction as evidenced by enhanced DPmax and reduced LVEDP in hearts isolated from aged female rats but not aged male rats (Figures 2(a) and 2(b)). In aged rats, PPC significantly improved coronary vascular dynamics, as indicated by enhanced CF and reduced CVR (P < 0.01) (Figures 2(c) and 2(d)), and improved myocardial contractility (P < 0.01) only in hearts isolated from females (Table 1). Consistent with the physiological data on cardiac functions, PPC significantly decreased the levels of cardiac enzymes (P < 0.01) and the myocardial infarct size (P < 0.01) in hearts from old female but not male rats (Figure 3(a) and Table 2). Taken together, the physiological, biochemical, and histological data indicate that PPC is an effective cardioprotective method in hearts isolated from young male and female rats and in hearts isolated from old female but not aged male rats.

3.2. PPC-Induced Cardiac Protection Is Revoked in Males with Left Ventricular Hypertrophy. In this set of experiments, we investigated the effect of LVH on the heart tolerance to ischemic injury and the effectiveness of PPC maneuver in its protection against I/R injury. Body weight corrected to tibia length was significantly (P < 0.05) higher in SHR males (289.73 [+ or -] 23.77) relative to the females (215.25 [+ or -] 2.73). Moreover, hearts of SHR males showed hypertrophy as indicated by a significant (P < 0.01) increase in heart weight corrected to tibia length (males, 0.39 [+ or -] 0.02; females, 0.34 [+ or -] 0.01). PPC maneuver was protective in nonhypertrophied hearts from males and females (Figures 3 and 4; Tables 1 and 2). Moreover, PPC did not induce a significant reduction in infarct size (Figure 2(b)) or cardiac enzyme release (Table 2). Interestingly however, PPC significantly improved left ventricular and coronary vascular dynamics (P < 0.001) (Figure 4 and Table 1), reduced infarct size (P < 0.001) (Figure 2(b)), and cardiac enzyme release (P < 0.01) (Table 2) in nonhypertrophied hearts from SHR females suggesting that the effectiveness of PPC as a cardioprotective maneuver is compromised in hypertrophied hearts.

3.3. Diabetes Mellitus Revokes the Cardioprotective Effects of PPC in Male and Female Rats. Diabetes mellitus did not have a significant effect on cardiac sensitivity to I/R injury (Figures 3 and 5; Tables 1 and 2). PPC did not induce significant improvements in the LV dynamics (Figures 5(a) and 5(b)), LV contractility (Table 1), or coronary vascular dynamics (Figures 5(c) and 5(d)) in hearts isolated from diabetic male and female rats. Furthermore, the presence of diabetes abrogated PPC-induced reduction in infarct size and release of cardiac enzymes following I/R injury equally in male and female rats (Figure 3(c) and Table 2), suggesting that under the conditions tested, PPC is not an efficient cardioprotective method in the diabetic rats.

3.4. PPC-Induced Cardiac Protection Is Preserved in Pregnant Rats. To address the effectiveness of PPC in the protection against I/R injury during pregnancy, hearts from nonpregnant and pregnant females at 19 and 21 days of gestation were subjected to I/R injury-followed PPC. The sensitivity of hearts from pregnant rats at 19 and 21 days of gestation to I/ R injury was not significantly different from that of hearts isolated from nonpregnant rats. PPC significantly normalized LV dynamics (P < 0.01), LV contractility (P < 0.001), and vascular dynamics (P < 0.01) in nonpregnant and pregnant rats (Figure 6 and Table 1). This effect was further confirmed by significant reductions in the infarct size (P < 0.001) (Figure 3(d)) and cardiac enzyme levels (P < 0.01; Table 2). These data indicate for the first time that PPC is an effective cardioprotective maneuver against I/R injury in pregnant rats.

4. Discussion

In the present study, we investigated the sensitivity of hearts isolated from male and female rats with clinically relevant scenarios (aging, LVH, diabetes mellitus, and pregnancy) to ischemic injury and the efficacy of PPC maneuver in protecting these hearts against I/R injury. We demonstrate that aging, LVH, diabetes mellitus, and pregnancy do not affect heart sensitivity to ischemic injury. Furthermore, our data suggest the existence of a novel gender-related discrepancy in PPC-induced cardiac protection in aged and spontaneously hypertensive rats. Heart protection in these animals was exclusively restricted to females. This, however, was not observed in diabetic rats. PPC-induced cardiac protection was revoked equally in diabetic male and female rats. Finally, we demonstrate, for the first time that PPC is an effective cardioprotective maneuver in pregnant rats (Figure 7).

The first clinical application of PPC was conducted by the Waltenberger and Prinzen groups when they demonstrated encouraging results on the potency of PPC in reducing the infarct size in STEMI patients. This, however, was accompanied by atrial and ventricular fibrillation in about 23% of the population, suggesting the requirement of additional technical optimization [11]. We realize that the successful clinical application of PPC maneuver would, therefore, require a detailed, in-depth analysis of various clinical scenarios existing in MI patients.

The protective effects of ischemic postconditioning were attenuated in aged mice [37]. We have therefore tested if PPC remains effective in protecting hearts from aged male and female rats against I/R injury. Our data suggest that aging does not enhance cardiac sensitivity to ischemic injury. Consistent with our previous data in rabbits, PPC was equally protective in younger male and female rats [25]. In aged rats, however, PPC was protective in a gender-specific manner. PPC protected the hearts isolated from

20-month-old female rats but not from male rats against I/ R injury. The observed resistance of aged male rats to cardioprotection is consistent with other studies [38, 39]. The exact reason(s) behind gender-related discrimination in cardioprotection is not understood. Several functional alterations were reported in intact hearts and in cardiomyocytes isolated from aged males. Dysfunctional regulation of mitochondrial permeability transition pore (mPTP) opening has been implicated in the loss of the cardioprotective effects of cyclosporine A in aged male cardiomyocytes [38]. Oxidative stress-induced mitochondrial damage was further reported in aged male hearts during ischemia resulting in mitochondria-derived cardiomyocytes injury [40]. Moreover, a significant increase in myocardial protein oxidation was reported in aged male hearts relative to younger controls [41]. Presence of basic lower levels of oxidants and higher levels of antioxidants in the female heart may explain the better protection to the female heart compared to male [42] which is attributed to the different nature of the mitochondrial functioning in male and female hearts [43]. Female hearts were proven to have higher levels of the protective phosphorylated AKT, GSK-3[beta], PKC, and anti-apoptotic factor BCl-2 [42]. Increased levels of the protective phosphorylated AKT, glycogen synthase kinase 3[beta] (GSK-3[beta]), PKC, and anti-apoptotic factor BCl-2 were reported in hearts from female rodents [42]. Moreover, alterations in cardiac inflammasome with aging could contribute to the observed resistance of aged male hearts to PPC-induced cardiac protection. Enhanced myocardial gene expression of proinflammatory cytokines was reported in animals [44] and clinical studies [45]. Collectively, this could potentially explain a lack of PPC-induced cardiac protection in males. Although protection to female rats could be due to the presence of the female hormone estrogen [6, 46], the exact cardioprotective factors conferring protection to females remain to be identified. A side-by-side comparison between males and females is required to identify possible female-specific cardioprotective factor(s).

Our data suggest that LVH does not increase cardiac sensitivity to ischemic injury. Moreover, we demonstrate that hearts from aged, 20-month-old, spontaneously hypertensive male rats are resistant to PPC-mediated cardioprotection. This was not the case in females where hearts were not hypertrophied and were responsive to PPC-induced cardiac protection as evident by reduction in the infarct size and cardiac enzyme release and normalization of contractility and coronary measures. We have previously demonstrated that estrogen receptor-beta protected murine female hearts from LVH [47]. The resistance of hypertrophied male hearts to PPC-mediated cardiac protection is consistent with other studies investigating the cardioprotective effects of captopril postconditioning [18, 19]; however, contrasting finding was also reported [48]. Attenuated signaling via reperfusion injury salvage kinase (RISK) GSK-3[beta] [49] and PI3K [50] were proposed as possible mechanisms of resistance to cardioprotection in hypertrophied hearts.

Here, we report that diabetes mellitus abolishes PPC-induced cardiac protection in a gender-independent manner. The finding that male and female hearts are equally affected by diabetes mellitus possibly suggests that cellular, metabolic, and physiological changes induced by diabetes are so dramatic that cannot be compensated for by factor(s) usually protecting female hearts against I/R injury. Diabetes-induced alterations in intracellular signaling pathways including the PI3K/Akt/GSK-3[beta] pathway and enhanced inflammation and oxidative stress were suggested as possible underlying mechanisms for the lack of protection [51-54]. Finally, taking into consideration the pronounced effects of diabetes mellitus on cardiac functions and the signaling pathways of postconditioning protection, the identification of an effective cardioprotective maneuver(s) in the diabetics remains essential.

We demonstrate that pregnancy does not affect the sensitivity of hearts to ischemic injury and PPC stands as an effective maneuver in reducing the infarct size and cardiac enzyme release and normalizing LV contractility and hemodynamics in hearts from pregnant rats. This could be due to pregnancy-induced increase in estrogen levels [55] which was reported to be cardioprotective. Estrogen-mediated cardiac protection involved inhibition of L-type calcium channel, opening of mito-KATP [56-58], and activation of mediators of the RISK pathway [59]. Nevertheless, the exact involvement of estrogen in PPC-induced cardiac protection in pregnant rats' hearts remains to be directly tested.

A potential limitation of this study is that the underlying molecular mechanisms were not investigated. The reason for that is the previous intensive studies conducted on the signaling pathways of postconditioning (RISK and SAFE pathways). These pathways were proven to be involved in the protection of almost all conditioning studies. The lack of heart protection presented in this study could be due to the alteration or remodeling of these signaling pathways by the clinical scenarios which revoked the protection. The signaling pathways of postconditioning protection reported to date in the literature explain the possible inducers for the protection and the lack of protection. We suggest some studies to unravel the alteration and remodeling of signaling pathways caused by comorbidities and other clinical scenarios.

We conclude that IHD in the presence of clinically relevant scenarios including aging, LVH, diabetes mellitus, and pregnancy does not affect cardiac sensitivity to ischemic injury. However, the efficacy of PPC as an effective cardioprotective maneuver is gender-dependent in aged and spontaneously hypertensive rats. PPC protected pregnant rats and loses its cardioprotective properties in diabetic rats in both genders equally.

LVH:      Left ventricle hypertrophy
IHD:      Ischemic heart disease
PPC:      Pacing postconditioning
I/R:      Ischemia and reperfusion
MI:       Myocardial infarction
CVDs:     Cardiovascular diseases
SD:       Sprague-Dawley
SHR:      Spontaneously hypertensive rat
STZ:      Streptozotocin
LVEDP:    Left ventricle end-diastolic pressure
DPmax:    Maximum developed pressure
CF:       Coronary flow
CVR:      Coronary vascular resistance
TTC:      Triphenyltetrazolium chloride control
CK:       Creatine kinase
LDH:      Lactate dehydrogenase
Ctr:      Control
GD:       Gestation day.

Data Availability

The data used to support the findings of this study are included within the article.


This work has been presented as conference abstract in the "Int'l Conference on Cardiovascular Medicine and Cardiopathy" and "British Cardiovascular Society Annual Conference."

Conflicts of Interest

There are no conflicts of interest.


The authors thank the technical assistance of Mr. Shaji Joseph and Ms. Anju Devassy at the Department of Physiology.


[1] D. J. Hausenloy, G. Baxter, R. Bell et al., "Translating novel strategies for cardioprotection: the Hatter workshop recommendations," Basic Research in Cardiology, vol. 105, no. 6, pp. 677-686, 2010.

[2] D. M. Yellon and D. J. Hausenloy, "Myocardial reperfusion injury," New England Journal of Medicine, vol. 357, no. 11, pp. 1121-1135, 2007.

[3] Z.-Q. Zhao, J. S. Corvera, M. E. Halkos et al., "Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning," American Journal of Physiology-Heart and Circulatory Physiology, vol. 285, no. 2, pp. H579-H588, 2003.

[4] J. Vinten-Johansen and W. Shi, "The science and clinical translation of remote postconditioning," Journal of Cardiovascular Medicine, vol. 14, no. 3, pp. 206-213, 2013.

[5] W. Y. Vanagt, R. N. Cornelussen, Q. P. Poulina et al., "Pacing-induced dys-synchrony preconditions rabbit myocardium against ischemia/reperfusion injury," Circulation, vol. 114, no. 1, pp. I-264-I-269, 2006.

[6] F. A. Babiker, S. Joseph, and J. Juggi, "The protective effects of 17beta-estradiol against ischemia-reperfusion injury and its effect on pacing postconditioning protection to the heart," Journal of Physiology and Biochemistry, vol. 70, no. 1, pp. 151-162, 2014.

[7] F. A. Babiker, I. Lorenzen-Schmidt, E. Mokelke et al., "Long-term protection and mechanism of pacing-induced postconditioning in the heart," Basic Research in Cardiology, vol. 105, no. 4, pp. 523-533, 2010.

[8] A. a. Abwainy, F. Babiker, S. Akhtar, and I. F. Benter, "Endogenous angiotensin-(1-7)/Mas receptor/NO pathway mediates the cardioprotective effects of pacing postconditioning," American Journal of Physiology-Heart and Circulatory Physiology, vol. 310, no. 1, pp. H104-H112, 2016.

[9] F. Babiker, A. Al-Jarallah, and S. Joseph, "The interplay between the renin angiotensin system and pacing postconditioning induced cardiac protection," PLoS One, vol. 11, no. 11, Article ID e0165777, 2016.

[10] F. A. Babiker, A. Al-Jarallah, and S. Joseph, "Understanding pacing postconditioning-mediated cardiac protection: a role of oxidative stress and a synergistic effect of adenosine," Journal of Physiology and Biochemistry, vol. 73, no. 2, pp. 175-185, 2017.

[11] J. Waltenberger, M. Gelissen, S. C. Bekkers et al., "Clinical pacing post-conditioning during revascularization after AMI," JACC: Cardiovascular Imaging, vol. 7, no. 6, pp. 620-626, 2014.

[12] J. B. Strait and E. G. Lakatta, "Aging-associated cardiovascular changes and their relationship to heart failure," Heart Failure Clinics, vol. 8, no. 1, pp. 143-164, 2012.

[13] G. H. Tofler, J. E. Muller, P. H. Stone et al., "Factors leading to shorter survival after acute myocardial infarction in patients ages 65 to 75 years compared with younger patients," American Journal of Cardiology, vol. 62, no. 13, pp. 860-867, 1988.

[14] M. Juhaszova, C. Rabuel, D. Zorov, E. Lakatta, and S. Sollott, "Protection in the aged heart: preventing the heart-break of old age?," Cardiovascular Research, vol. 66, no. 2, pp. 233-244, 2005.

[15] K. Boengler, R. Schulz, and G. Heusch, "Loss of cardioprotection with ageing," Cardiovascular Research, vol. 83, no. 2, pp. 247-261, 2009.

[16] P. G. Anderson, S. P. Bishop, and S. B. Digerness, "Transmural progression of morphologic changes during ischemic contracture and reperfusion in the normal and hypertrophied rat heart," American Journal of Pathology, vol. 129, pp. 152-167, 1987.

[17] J. M. McLenachan, E. Henderson, K. I. Morris, and H. J. Dargie, "Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy," New England Journal of Medicine, vol. 317, no. 13, pp. 787-792, 1987.

[18] C. Penna, F. Tullio, F. Moro, A. Folino, A. Merlino, and P. Pagliaro, "Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats," Basic Research in Cardiology, vol. 105, no. 2, pp. 181-192, 2010.

[19] C. Penna, F. Tullio, M.-G. Perrelli et al., "Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is lost as cardiac hypertrophy develops in nandrolone treated rats," Basic Research in Cardiology, vol. 106, no. 3, pp. 409-420, 2011.

[20] B. A. Vakili, P. M. Okin, and R. B. Devereux, "Prognostic implications of left ventricular hypertrophy," American Heart Journal, vol. 141, no. 3, pp. 334-341, 2001.

[21] W. B. Kannel and D. L. McGee, "Diabetes and cardiovascular disease. The Framingham study," Journal of the American Medical Association, vol. 241, no. 19, pp. 2035-2038, 1979.

[22] S. P. Marso, T. Miller, B. D. Rutherford et al., "Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial)," American Journal of Cardiology, vol. 100, no. 2, pp. 206-210, 2007.

[23] J. Gamble and G. D. Lopaschuk, "Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1225, no. 2, pp. 191-199, 1994.

[24] P. Balakumar and N. K. Sharma, "Healing the diabetic heart: does myocardial preconditioning work?," Cellular Signalling, vol. 24, no. 1, pp. 53-59, 2012.

[25] F. A. Babiker, J. van Golde, W. Y. Vanagt, and F. W. Prinzen, "Pacing postconditioning: impact of pacing algorithm, gender, and diabetes on its myocardial protective effects," Journal of Cardiovascular Translational Research, vol. 5, no. 5, pp. 727-734, 2012.

[26] I. F. Benter, F. Babiker, I. Al-Rashdan, M. Yousif, and S. Akhtar, "RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes," Journal of Diabetes Research, vol. 2013, Article ID 427693, 14 pages, 2013.

[27] H. Lameijer, M. A. M. Kampman, M. A. Oudijk, and P. G. Pieper, "Ischaemic heart disease during pregnancy or post-partum: systematic review and case series," Netherlands Heart Journal, vol. 23, no. 5, pp. 249-257, 2015.

[28] P. Whittaker, S. Macphail, and T. Lind, "Serial hematologic changes and pregnancy outcome," Obstetrics & Gynecology, vol. 88, no. 1, pp. 33-39, 1996.

[29] A. Roth and U. Elkayam, "Acute myocardial infarction associated with pregnancy," Annals of Internal Medicine, vol. 125, no. 9, pp. 751-762, 1996.

[30] J. M. Roberts and J. M. Catov, "Aspirin for pre-eclampsia: compelling data on benefit and risk," The Lancet, vol. 369, no. 9575, pp. 1765-1766, 2007.

[31] A. Khalaf and F. Babiker, "Discrepancy in calcium release from the sarcoplasmic reticulum and intracellular acidic stores for the protection of the heart against ischemia/ reperfusion injury," Journal of Physiology and Biochemistry, vol. 72, no. 3, pp. 495-508, 2016.

[32] H. H. Ng, C. H. Leo, D. Prakoso, C. Qin, R. H. Ritchie, and L. J. Parry, "Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes," Scientific Reports, vol. 7, no. 1, article 39604, 2017.

[33] R. Badalzadeh, M. Mohammadi, M. Najafi, N. Ahmadiasl, S. Farajnia, and H. Ebrahimi, "The additive effects of ischemic postconditioning and cyclosporine-A on nitric oxide activity and functions of diabetic myocardium injured by ischemia/ reperfusion," Journal of Cardiovascular Pharmacology and Therapeutics, vol. 17, no. 2, pp. 181-189, 2012.

[34] M. Abul, M. D. Al-Bader, and A. Mouihate, "Exposure to synthetic glucocorticoids during pregnancy alters the expression of p73 gene variants in fetal brains in a sex-specific manner," Brain Research, vol. 1707, pp. 117-123, 2019.

[35] M. D. Al-Bader, S. A. Jasem, and N. Kilarkaje, "Carbenoxolone exposure during late gestation in rats alters placental expressions of p53 and estrogen receptors," European Journal of Pharmacology, vol. 791, pp. 675-685, 2016.

[36] R. Ferrera, S. Benhabbouche, J. C. Bopassa, B. Li, and M. Ovize, "One hour reperfusion is enough to assess function and infarct size with TTC staining in Langendorff rat model," Cardiovascular Drugs and Therapy, vol. 23, no. 4, pp. 327-331, 2009.

[37] K. Boengler, D. Hilfikerkleiner, H. Drexler, G. Heusch, and R. Schulz, "The myocardial JAK/STAT pathway: from protection to failure," Pharmacology & Therapeutics, vol. 120, no. 2, pp. 172-185, 2008.

[38] X.-X. Hu, L. Fu, Y. Li et al., "The cardioprotective effect of vitamin E (Alpha-Tocopherol) is strongly related to age and gender in mice," PLoS One, vol. 10, no. 9, Article ID e0137405, 2015.

[39] H. Li, D. Chen, N. Fang, Y. Yao, and L. Li, "Age-associated differences in response to sevoflurane postconditioning in rats," Scandinavian Cardiovascular Journal, vol. 50, no. 2, pp. 128-136, 2016.

[40] E. J. Lesnefsky and C. L. Hoppel, "Cardiolipin as an oxidative target in cardiac mitochondria in the aged rat," Biochimica et Biophysica Acta (BBA)-Bioenergetics, vol. 1777, no. 7-8, pp. 1020-1027, 2008.

[41] S. Besse, A. L. Bulteau, F. Boucher, B. Riou, B. Swynghedauw, and J. de Leiris, "Antioxidant treatment prevents cardiac protein oxidation after ischemia-reperfusion and improves myocardial function and coronary perfusion in senescent hearts," Journal of Physiology and Pharmacology, vol. 57, pp. 541-552, 2006.

[42] A. Ciocci Pardo, S. Scuri, L. F. Gonzalez Arbelaez, C. Caldiz, J. Fantinelli, and S. M. Mosca, "Survival kinase-dependent pathways contribute to gender difference in the response to myocardial ischemia-reperfusion and ischemic post-conditioning," Cardiovascular Pathology, vol. 33, pp. 19-26, 2018.

[43] A. R. Khalifa, E. A. Abdel-Rahman, A. M. Mahmoud et al., "Sex-specific differences in mitochondria biogenesis, morphology, respiratory function, and ROS homeostasis in young mouse heart and brain," Physiological Reports, vol. 5, 2017.

[44] S. Batkai, M. Rajesh, P. Mukhopadhyay et al., "Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase," American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 2, pp. H909-H918, 2007.

[45] S. L. Klein, A. Jedlicka, and A. Pekosz, "The Xs and Y of immune responses to viral vaccines," The Lancet Infectious Diseases, vol. 10, no. 5, pp. 338-349, 2010.

[46] F. A. Babiker, D. J. Lips, E. Delvaux et al., "Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms," Acta Physiologica, vol. 189, no. 1, pp. 23-31, 2007.

[47] F. A. Babiker, D. Lips, R. Meyer et al., "Estrogen receptor [beta] protects the murine heart against left ventricular hypertrophy," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1524-1530, 2006.

[48] J. C. Fantinelli, L. F. Gonzalez Arbelaez, I. A. Perez Nunez, and S. M. Mosca, "Protective effects of N-(2-mercaptopropionyl)-glycine against ischemia-reperfusion injury in hypertrophied hearts," Experimental and Molecular Pathology, vol. 94, no. 1, pp. 277-284, 2013.

[49] L.-L. Ma, F.-J. Zhang, F.-J. Kong et al., "Hypertrophied myocardium is refractory to sevoflurane-induced protection with alteration of reperfusion injury salvage kinase/glycogen synthase kinase 3[beta] signals," Shock, vol. 40, no. 3, pp. 217-221, 2013.

[50] I. Friehs, C. Stamm, H. Cao-Danh, F. X. McGowan, and P. J. del Nido, "Insulin-like growth factor-1 improves post-ischemic recovery in hypertrophied hearts," Annals of Thoracic Surgery, vol. 72, no. 5, pp. 1650-1656, 2001.

[51] A. Rana, N. Goyal, A. Ahlawat, S. Jamwal, B. Reddy, and S. Sharma, "Mechanisms involved in attenuated cardioprotective role of ischemic preconditioning in metabolic disorders," Perfusion, vol. 30, no. 2, pp. 94-105, 2015.

[52] N. Frangogiannis, C. W. Smith, and M. L. Entman, "The inflammatory response in myocardial infarction," Cardiovascular Research, vol. 53, no. 1, pp. 31-47, 2002.

[53] T. Miki, T. Itoh, D. Sunaga, and T. Miura, "Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning," Cardiovascular Diabetology, vol. 11, no. 1, p. 67, 2012.

[54] T. Miki, T. Miura, H. Hotta et al., "Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3[beta]-mediated suppression of mitochondrial permeability transition," Diabetes, vol. 58, no. 12, pp. 2863-2872, 2009.

[55] S. G. Paranjape, A. V. Turankar, S. L. Wakode, and G. N. Dakhale, "Estrogen protection against coronary heart disease: are the relevant effects of estrogen mediated through its effects on uterus-such as the induction of menstruation, increased bleeding, and the facilitation of pregnancy?," Medical Hypotheses, vol. 65, no. 4, pp. 725-727, 2005.

[56] E. Cairrao, E. Alvarez, J. M. Carvas, A. J. Santos-Silva, and I. Verde, "Non-genomic vasorelaxant effects of 17[beta]-estradiol and progesterone in rat aorta are mediated by L-type [Ca.sup.2+] current inhibition," Acta Pharmacologica Sinica, vol. 33, no. 5, pp. 615-624, 2012.

[57] T.-M. Lee, S.-F. Su, C.-C. Tsai, Y.-T. Lee, and C.-H. Tsai, "Cardioprotective effects of 17[beta]-estradiol produced by activation of mitochondrial ATP-sensitive [K.sup.+] channels in canine hearts," Journal of Molecular and Cellular Cardiology, vol. 32, no. 7, pp. 1147-1158, 2000.

[58] L. Prokai and J. W. Simpkins, "Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds," Pharmacology & Therapeutics, vol. 114, no. 1, pp. 1-12, 2007.

[59] M. P. Haynes, D. Sinha, K. S. Russell et al., "Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells," Circulation Research, vol. 87, no. 8, pp. 677-682, 2000.

Fawzi Babiker [ID], (1) Aishah Al-Jarallah [ID], (2) and Mariam Al-Awadi (1)

(1) Department of Physiology, Faculty of Medicine, Health Science Center, Kuwait University, Jabriya, Kuwait

(2) Biochemistry, Faculty of Medicine, Health Science Center, Kuwait University, Jabriya, Kuwait

Correspondence should be addressed to Fawzi Babiker;

Received 15 October 2018; Revised 12 February 2019; Accepted 25 March 2019; Published 6 May 2019

Academic Editor: Vincenzo Russo

Caption: Figure 1: Illustration of the protocols and experimental groups used in the study. LVH, left ventricle hypertrophy.

Caption: Figure 2: Effects of PPC on left ventricular and coronary vascular dynamics in hearts isolated from young and aging rats. PPC-mediated protection of the heart against I/R injury in hearts isolated from 20-month-old male and female rats (n = 6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means [+ or -] SEM. PPC, pacing postconditioning. * P < 0.01 compared to the respective control. ([dagger]) P < 0.01 compared to the ischemic period.

Caption: Figure 3: Histological assessment of ischemic injury. Infarct size presented area as a percentage of left ventricle area in the experimental models of aging (a), left ventricular hypertrophy (b), diabetes mellitus (c), and pregnancy (d). PPC, pacing postconditioning. *P < 0.01 compared to the respective control.

Caption: Figure 4: Effects of PPC on left ventricular and coronary vascular dynamics in hypertrophied and nonhypertrophied hearts. PPC-mediated protection in hearts with left ventricle hypertrophy (n = 6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means [+ or -] SEM. PPC, pacing postconditioning. * P < 0.01 compared to the respective control. ([dagger]) P < 0.01 compared to the ischemic period.

Caption: Figure 5: Effects of PPC on left ventricular and coronary vascular dynamics hearts isolated from nondiabetic and diabetic rats. PPC-mediated protection in hearts isolated from diabetic male and female rats (n = 6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means [+ or -] SEM. Ctr, control; PPC, pacing postconditioning. * P < 0.01 compared to the respective control. ([dagger]) P < 0.01 compared to the ischemic period.

Caption: Figure 6: Effects of PPC on left ventricular and coronary vascular dynamics in hearts isolated from nonpregnant and pregnant rats. PPC-mediated protection in hearts isolated from pregnant rats at 19 or 21 gestation days (n = 6 per group). Post-ischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means [+ or -] SEM. Ctr, control; PPC, pacing postconditioning; GD, gestation day. * P < 0.01 compared to the respective control. ([dagger]) P < 0.01 compared to the ischemic period.

Caption: Figure 7: Effects of comorbidities on PPC-induced cardiac protection. Schematic representation summarizing the results of the study.
Table 1: Effects of ischemia-reperfusion and PPC on heart

Treatment                                  +dP/dt

                              Ischemia              Reperfusion

Ctr male                54.32 [+ or -] 3.48     58.89 [+ or -] 6.94
Ctr male + PPC          50.66 [+ or -] 3.55    80.45 [+ or -] 4.64 *
Ctr old male            55.30 [+ or -] 4.31     56.13 [+ or -] 4.53
Old male + PPC          49.78 [+ or -] 1.86     49.66 [+ or -] 2.88
Ctr female              54.59 [+ or -] 4.41     48.16 [+ or -] 6.70
Ctr female + PPC        50.66 [+ or -] 3.55    75.75 [+ or -] 3.43 *
Ctr old female          49.22 [+ or -] 2.09     48.28 [+ or -] 3.77
Ctr old female + PPC    56.08 [+ or -] 3.10    69.08 [+ or -] 4.75 *
Ctr male                59.31 [+ or -] 6.34     64.88 [+ or -] 4.99
Ctr male + PPC          50.66 [+ or -] 4.10    81.27 [+ or -] 3.02 *
Ctr LVH male            66.45 [+ or -] 5.47     76.57 [+ or -] 4.43
LVH male + PPC          69.32 [+ or -] 6.87     68.64 [+ or -] 2.78
Ctr female              53.82 [+ or -] 6.07     55.56 [+ or -] 6.25
Ctr female + PPC        62.63 [+ or -] 4.68    82.08 [+ or -] 2.96 *
Ctr LVH female          68.20 [+ or -] 7.11     72.83 [+ or -] 6.33
LVH female + PPC        56.99 [+ or -] 7.82    85.57 [+ or -] 7.14 *
Ctr diabetic male       59.31 [+ or -] 6.34     64.88 [+ or -] 4.99
Diabetic male + PPC     55.86 [+ or -] 4.02     59.29 [+ or -] 8.94
Ctr diabetic female     58.98 [+ or -] 5.09     55.04 [+ or -] 8.03
Diabetic female + PPC   53.05 [+ or -] 4.18     59.70 [+ or -] 8.90
Ctr female 19 GD        49.45 [+ or -] 2.59     63.63 [+ or -] 1.81
Female 19 GD + PPC      50.46 [+ or -] 3.36    72.59 [+ or -] 1.38 *
Ctr female 21 GD        47.19 [+ or -] 2.04     59.78 [+ or -] 1.46
Female 21 GD + PPC      49.79 [+ or -] 2.09    72.80 [+ or -] 1.88 *

Treatment                                 -dP/dt

                              Ischemia              Reperfusion

Ctr male                49.22 [+ or -] 2.09     48.28 [+ or -] 3.77
Ctr male + PPC          50.13 [+ or -] 3.83    80.22 [+ or -] 2.48 *
Ctr old male            56.32 [+ or -] 4.13     49.53 [+ or -] 3.94
Old male + PPC          58.86 [+ or -] 3.81     61.51 [+ or -] 4.33
Ctr female              52.45 [+ or -] 3.27     50.81 [+ or -] 3.99
Ctr female + PPC        50.13 [+ or -] 3.83    80.22 [+ or -] 2.48 *
Ctr old female          60.22 [+ or -] 4.14     59.91 [+ or -] 5.43
Ctr old female + PPC    56.62 [+ or -] 4.65    68.56 [+ or -] 2.77 *
Ctr male                54.54 [+ or -] 4.94     50.74 [+ or -] 3.07
Ctr male + PPC          52.57 [+ or -] 2.46    78.81 [+ or -] 3.66 *
Ctr LVH male            67.44 [+ or -] 2.43     76.99 [+ or -] 3.53
LVH male + PPC          68.74 [+ or -] 8.50     80.72 [+ or -] 5.22
Ctr female              54.77 [+ or -] 3.29     57.84 [+ or -] 5.05
Ctr female + PPC        61.76 [+ or -] 4.05    78.49 [+ or -] 4.64 *
Ctr LVH female          73.27 [+ or -] 9.72     71.35 [+ or -] 4.48
LVH female + PPC        52.61 [+ or -] 3.51    70.46 [+ or -] 6.42 *
Ctr diabetic male       54.54 [+ or -] 4.94     50.74 [+ or -] 3.07
Diabetic male + PPC     49.06 [+ or -] 2.68     47.53 [+ or -] 4.77
Ctr diabetic female     56.15 [+ or -] 3.46     58.39 [+ or -] 4.79
Diabetic female + PPC   47.84 [+ or -] 2.02     48.16 [+ or -] 4.68
Ctr female 19 GD        51.97 [+ or -] 1.24     65.17 [+ or -] 0.66
Female 19 GD + PPC      55.97 [+ or -] 1.57    71.27 [+ or -] 1.29 *
Ctr female 21 GD        47.84 [+ or -] 1.69     64.00 [+ or -] 0.43
Female 21 GD + PPC      50.95 [+ or -] 3.28    71.19 [+ or -] 0.63 *

Ctr: control; PPC: pacing postconditioning; LVH: left ventricle
hypertrophy; GD: gestation day. * P < 0.01 compared to the respective

Table 2: Effects of ischemia-reperfusion and PPC on cardiac
enzymes levels.

Treatment                        CK IU/L           P value

Ctr male                   21.32 [+ or -] 1.84        --
Ctr male + PPC            9.41 [+ or -] 1.87 *      0.001
Ctr old male               21.13 [+ or -] 1.12        --
Old male + PPC             20.23 [+ or -] 1.43      0.231
Ctr female                 20.13 [+ or -] 1.82        --
Ctr female + PPC          10.21 [+ or -] 1.71 *     0.001
Ctr old female             20.13 [+ or -] 1.86        --
Old female + PPC          10.53 [+ or -] 1.24 *     0.001
Ctr male                   23.41 [+ or -] 2.13        --
Ctr male + PPC            10.23 [+ or -] 1.43 *     0.001
Ctr LVH male               23.54 [+ or -] 2.63        --
LVH male + PPC             21.39 [+ or -] 2.02      0.315
Ctr female                 20.85 [+ or -] 1.93        --
Ctr female + PPC          10.98 [+ or -] 1.61 *     0.001
Ctr LVH female             22.10 [+ or -] 1.83        --
LVH female + PPC          9.14 [+ or -] 1.19 *      0.001
Ctr diabetic male          23.75 [+ or -] 2.13        --
Diabetic male + PPC        21.72 [+ or -] 1.71      0.524
Ctr diabetic female        20.63 [+ or -] 2.85        --
Diabetic female + PPC      21.31 [+ or -] 1.86      0.463
Ctr female 19 GD           20.42 [+ or -] 1.66        --
Female 19 GD + PPC         9.92 [+ or -] 1.12*      0.001
Ctr female 21 GD           21.33 [+ or -] 1.62        --
Female 21 GD + PPC        9.87 [+ or -] 1.95 *      0.001

Treatment                       LDH IU/L           P value

Ctr male                   20.73 [+ or -] 1.37        --
Ctr male + PPC            7.94 [+ or -] 1.83 *      0.001
Ctr old male               18.62 [+ or -] 2.10        --
Old male + PPC             18.42 [+ or -] 2.02      0.411
Ctr female                 18.93 [+ or -] 1.11        --
Ctr female + PPC          9.95 [+ or -] 1.64 *      0.001
Ctr old female             16.47 [+ or -] 1.82        --
Old female + PPC          9.03 [+ or -] 1.65 *      0.001
Ctr male                   19.21 [+ or -] 1.98        --
Ctr male + PPC            8.11 [+ or -] 2.13 *      0.001
Ctr LVH male               16.22 [+ or -] 1.43        --
LVH male + PPC             17.53 [+ or -] 1.45      0.314
Ctr female                 17.97 [+ or -] 1.36        --
Ctr female + PPC          9.14 [+ or -] 1.82 *      0.001
Ctr LVH female             16.31 [+ or -] 1.92        --
LVH female + PPC          10.63 [+ or -] 1.92 *      0.01
Ctr diabetic male          17.52 [+ or -] 1.61        --
Diabetic male + PPC        19.27 [+ or -] 2.13      0.243
Ctr diabetic female        18.92 [+ or -] 1.62        --
Diabetic female + PPC      18.26 [+ or -] 1.23      0.217
Ctr female 19 GD           16.24 [+ or -] 1.23        --
Female 19 GD + PPC        8.31 [+ or -] 1.14 *      0.001
Ctr female 21 GD           17.24 [+ or -] 1.38        --
Female 21 GD + PPC        8.05 [+ or -] 1.23 *      0.001

CK: creatine kinase; LDH: lactate dehydrogenase; Ctr: control; PPC:
pacing postconditioning; LVH: left ventricle hypertrophy; GD:
gestation day. * P < 0.001 compared to the respective control.
COPYRIGHT 2019 COPYRIGHT 2010 SAGE-Hindawi Access to Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Babiker, Fawzi; Jarallah, Aishah Al-; Awadi, Mariam Al-
Publication:Cardiology Research and Practice
Date:May 31, 2019
Previous Article:Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study.
Next Article:Hypereosinophilic Syndrome, Cardiomyopathies, and Sudden Cardiac Death in Superinvasive Opisthorchiasis.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |